SUMER JACQUELYN L 4

What Happened
Jacquelyn L. Sumer, Chief Legal Officer of Cullinan Therapeutics (CGEM), was granted a derivative equity award for 230,000 shares on 2026-02-18. The award is reported at a $0.00 price (no cash paid at grant). This was a compensation grant (award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-18; Form 4 filed 2026-02-19 (timely filing).
• Reported transaction type/code: A (Grant/Award/Other acquisition) — 230,000 shares, $0.00 per share (derivative).
• Vesting: per footnote — vests over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary.
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of immediate sale or cashless exercise; this is a compensation award, not a market trade.

Context
This is a standard executive equity grant intended as compensation/incentive and should not be read as an immediate market buy or sell. Because it vests over time, it aligns the officer’s interests with the company’s longer-term performance; it does not provide an immediate liquidity event or cash value in the filing itself.